Presented in part at the American Association for the Study of Liver Diseases, 56th Annual Meeting, San Francisco, CA, November 11-15, 2005.
Article first published online: 27 DEC 2006
Copyright © 2006 American Association for the Study of Liver Diseases
Volume 13, Issue 1, pages 122–129, January 2007
How to Cite
Terrault, N. A., Shiffman, M. L., Lok, A. S.F., Saab, S., Tong, L., Brown, R. S., Everson, G. T., Reddy, K. R., Fair, J. H., Kulik, L. M., Pruett, T. L. and Seeff, L. B. (2007), Outcomes in hepatitis C virus–infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl, 13: 122–129. doi: 10.1002/lt.20995
Publication number 2 of the Adult-to-Adult Living Donor Liver Transplantation Cohort Study.
Supplemental data have been supplied by the University Renal Research and Education Association as the contractor for the Scientific Registry of Transplant Recipients. The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy of or interpretation by the Scientific Registry of Transplant Recipients or the U.S. government.
See Editorial on Page 18
Telephone: 734-998-6580; FAX: 734-998-6620
- Issue published online: 27 DEC 2006
- Article first published online: 27 DEC 2006
- Manuscript Accepted: 21 AUG 2006
- Manuscript Received: 18 APR 2006
- National Institutes of Health National Institute of Diabetes & Digestive & Kidney Diseases. Grant Numbers: U01-DK62536, U01-DK62444, U01-DK62467, U01-DK62483, U01-DK62484, U01-DK62494, U01-DK62496, U01-DK62498, U01-DK62505, U01-DK62531
- American Society of Transplant Surgeons
- U.S. Department of Health and Human Services, Health Resources and Services Administration
In this retrospective study of hepatitis C virus (HCV)–infected transplant recipients in the 9-center Adult to Adult Living Donor Liver Transplantation Cohort Study, graft and patient survival and the development of advanced fibrosis were compared among 181 living donor liver transplant (LDLT) recipients and 94 deceased donor liver transplant (DDLT) recipients. Overall 3-year graft and patient survival were 68% and 74% in LDLT, and 80% and 82% in DDLT, respectively. Graft survival, but not patient survival, was significantly lower for LDLT compared to DDLT (P = 0.04 and P = 0.20, respectively). Further analyses demonstrated lower graft and patient survival among the first 20 LDLT cases at each center (LDLT ⩽20) compared to later cases (LDLT > 20; P = 0.002 and P = 0.002, respectively) and DDLT recipients (P < 0.001 and P = 0.008, respectively). Graft and patient survival in LDLT >20 and DDLT were not significantly different (P = 0.66 and P = 0.74, respectively). Overall, 3-year graft survival for DDLT, LDLT >20, and LDLT ⩽20 were 80%, 79% and 55%, with similar results conditional on survival to 90 days (84%, 87% and 68%, respectively). Predictors of graft loss beyond 90 days included LDLT ⩽20 vs. DDLT (hazard ratio [HR] = 2.1, P = 0.04), pretransplant hepatocellular carcinoma (HCC) (HR = 2.21, P = 0.03) and model for end-stage liver disease (MELD) at transplantation (HR = 1.24, P = 0.04). In conclusion, 3-year graft and patient survival in HCV-infected recipients of DDLT and LDLT >20 were not significantly different. Important predictors of graft loss in HCV-infected patients were limited LDLT experience, pretransplant HCC, and higher MELD at transplantation. Liver Transpl 13:122–129, 2007. © 2006 AASLD.